U-VUE Biomarker Datasheet - CD45RO
|Main cell types:||T cells|
|Subcellular Location:||Plasma membrane|
|Positive control:||Tonsil, Spleen|
CD45RO is expressed on activated and memory T cells, some B cell subsets, activated monocytes/macrophages, and granulocytes. Lack of CD45RO on T cells indicates naive T cell subsets while CD45RO expression indicated previous antigen exposure and defines the memory T cell subset. High density of CD45RO+ T cells in solid tumors is associated with a better prognosis.
IHC: Anti-CD45RO antibody [UCH-L1] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
IHC: Anti-CD45RO antibody conjugate [UCH-L1] staining normal tonsil FFPE tissue (brown). Hematoxylin counterstain in blue.
ISP: Anti-CD45RO antibody conjugate [UCH-L1] staining normal tonsil FFPE tissue (green). Nuclear counterstain in blue.
- Tarhini, Ahmad A et al. “Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.” PloS one, vol. 9,2 e87705. 3 Feb. 2014. DOI: 10.1371/journal.pone.0087705
- Zlobec, Inti et al. “Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types.” Journal of translational medicine, vol. 11 104. 30 Apr. 2013. DOI: 10.1186/1479-5876-11-104
- Norton, A J et al. “Monoclonal antibody (UCHL1) that recognises normal and neoplastic T cells in routinely fixed tissues.” Journal of clinical pathology, vol. 39,4 (1986): 399-405. DOI: 10.1136/jcp.39.4.399
Each lot of antibody conjugate reagent is quality control tested on positive control tissue and reviewed by Ultivue’s Pathology and Biomarker Analytics group to ensure appropriate staining patterns and signal intensity.
This U-VUE Antibody Conjugate is for Research Use Only. Not for Diagnostic purposes.